Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma
Authors
Keywords
-
Journal
Neurosurgical Focus
Volume 38, Issue 3, Pages E6
Publisher
Journal of Neurosurgery Publishing Group (JNSPG)
Online
2015-03-02
DOI
10.3171/2014.11.focus14716
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stereotactic radiosurgery: A new paradigm for melanoma and renal cell carcinoma spine metastases.
- (2017) A. Thiagaragan et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of stereotactic radiosurgery for the treatment of spinal axis tumors: A review
- (2014) Mohamad Bydon et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Radiobiological basis of SBRT and SRS
- (2014) Chang W. Song et al. International Journal of Clinical Oncology
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma
- (2014) Darshil J. Shah et al. MAYO CLINIC PROCEEDINGS
- Spine radiosurgery for spinal metastases: indications, technique and outcome
- (2014) Ran Harel et al. NEUROLOGICAL RESEARCH
- Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis
- (2014) Matthias Guckenberger et al. Radiation Oncology
- Stereotactic radiosurgery in the treatment of brain metastases: The current evidence
- (2013) Bodo Lippitz et al. CANCER TREATMENT REVIEWS
- Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients
- (2013) Ilya Laufer et al. JOURNAL OF NEUROSURGERY-SPINE
- High intensity focused ultrasound ablation and antitumor immune response
- (2013) Feng Wu JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
- Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases
- (2013) Arjun Sahgal et al. LANCET ONCOLOGY
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The NOMS Framework: Approach to the Treatment of Spinal Metastatic Tumors
- (2013) I. Laufer et al. ONCOLOGIST
- The Human Melanoma Side Population Displays Molecular and Functional Characteristics of Enriched Chemoresistance and Tumorigenesis
- (2013) Jasper Wouters et al. PLoS One
- Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2
- (2013) M. P. O'Connell et al. Cancer Discovery
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Stereotactic Body Radiation Therapy in Spinal Metastases
- (2012) Kamran A. Ahmed et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival
- (2012) Jonathan P. S. Knisely et al. JOURNAL OF NEUROSURGERY
- Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
- (2012) Eva Ellebaek et al. Journal of Translational Medicine
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Increasing Incidence of Melanoma Among Young Adults: An Epidemiological Study in Olmsted County, Minnesota
- (2012) Kurtis B. Reed et al. MAYO CLINIC PROCEEDINGS
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management
- (2012) Pooya Jahanshahi et al. Frontiers in Oncology
- White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy
- (2011) J. Weber et al. CLINICAL CANCER RESEARCH
- Immunomodulatory cytokines as therapeutic agents for melanoma
- (2011) Courtney Nicholas et al. Immunotherapy
- Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy
- (2011) Orit Itzhaki et al. JOURNAL OF IMMUNOTHERAPY
- Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
- (2011) Jeffrey S. Weber et al. MELANOMA RESEARCH
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- (2011) C. Garbe et al. ONCOLOGIST
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Interferon-β-1b
- (2010) Greg L. Plosker CNS DRUGS
- Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
- (2010) Milan J. Sonneveld et al. HEPATOLOGY
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- En Bloc Resection for Primary and Metastatic Tumors of the Spine
- (2010) Jordan M. Cloyd et al. NEUROSURGERY
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Cytokines in the Management of High Risk or Advanced Breast Cancer: An Update and Expectation
- (2009) A. Carpi et al. CURRENT CANCER DRUG TARGETS
- Melanoma-induced brain metastases
- (2008) Robert R McWilliams et al. Expert Review of Anticancer Therapy
- Stereotactic Body Radiosurgery for Spinal Metastases: A Critical Review
- (2008) Arjun Sahgal et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- High-Dose, Single-Fraction Image-Guided Intensity-Modulated Radiotherapy for Metastatic Spinal Lesions
- (2008) Yoshiya Yamada et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Neuropsychiatric disorders related to interferon and interleukins treatment
- (2008) Aye Mu Myint et al. METABOLIC BRAIN DISEASE
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
- (2008) F Stephen Hodi et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started